Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
Holding RZLT?
Track your performance easily
RZLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $6.19
Previous Close$5.29
Volume441.41K
Average Volume (3M)391.53K
Market Cap
$306.52M
Enterprise Value$200.30M
Total Cash (Recent Filing)$108.30M
Total Debt (Recent Filing)$2.08M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Feb 05, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding57,943,066
10 Day Avg. Volume415,647
30 Day Avg. Volume391,533
Standard Deviation0.25
R-Squared0.00281
Alpha0.00483
Financial Highlights & Ratios
Price to Book (P/B)2.70
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.21
Forecast
1Y Price Target
$11.75Price Target Upside122.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Rezolute News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Regulatory ProgressThe FDA lifted the partial clinical hold on the RZ358 program, allowing the ongoing global Phase III study to include U.S. sites.
Market Potential And ExpansionRZ358 should benefit approximately 75% of the estimated 3,500 congenital hyperinsulinism patients in the U.S. and EU, which require pharmacological treatment.
Product Efficacy And SafetyPublished or presented data have demonstrated promising clinical benefit with patients refractory to multiple current standard of care achieving glycemic control after RZ358 treatment.
Bears Say
Clinical TrialsSuccess in clinical trials will be essential for Rezolute to market its products, but clinical success is not guaranteed.
Financial PerformanceRezolute is not generating revenue and has capital needs that exceed the current cash balance.
Revenue GenerationRezolute is not generating revenue and has capital needs that exceed current cash balance.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $0.72 and its highest was $6.18 in the past 12 months.
What is Rezolute’s market cap?
Currently, no data Available
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Feb 05, 2025 which is in 74 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.113.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -$0.25.
How many shares outstanding does Rezolute have?
Rezolute has 57,943,066 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went down -2.448%.
Which hedge fund is a major shareholder of Rezolute?
Among the largest hedge funds holding Rezolute’s share is Blackstone Inc.. It holds Rezolute’s shares valued at 8M.
---
Rezolute Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (122.12% Upside)
$11.75 (122.12% Upside)
Hedge Fund Trend
Increased
By 207.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
604.39%
12-Months-Change
Fundamentals
Return on Equity
-63.88%
Trailing 12-Months
Asset Growth
9.22%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
---
RZLT Stock 12 Month Forecast
Average Price Target
$11.75
▲(122.12% Upside)
Technical Analysis
Best Analysts Covering RZLT
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+84.41%
reiterated a buy rating 2 months ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +84.41% per trade.
---